The CB 2 cannabinoid receptor has been implicated in the regulation of intestinal inflammation. Following on from the promising activity of a series of 4-oxo-1,4-dihydroquinoline-3-carboxamide, we developed constrained analogues based on a 2H-pyrazolo[4,3-c]quinolin-3(5H)-one scaffold, with improved affinity for the hCB 2 receptor and had very high selectivity over the hCB 1 receptor. Importantly, the lead of this series (26, hCB 2 : K i = 0.39 nM, hCB 1 : K i > 3000 nM) was found to protect mice against experimental colitis after oral administration.
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ABSTRACT: The CB 2 cannabinoid receptor has been implicated in the regulation of intestinal inflammation. Following on from the promising activity of a series of 4-oxo-1,4-dihydroquinoline-3-carboxamide, we developed constrained analogues based on a 2H-pyrazolo[4,3-c]quinolin-3(5H)-one scaffold, with improved affinity for the hCB 2 receptor and had very high selectivity over the hCB 1 receptor. Importantly, the lead of this series (26, hCB 2 : K i = 0.39 nM, hCB 1 : K i > 3000 nM) was found to protect mice against experimental colitis after oral administration. KEYWORDS: Cannabinoid receptor, endocannabinoid, colitis, inflammatory bowel disease, quinolone, conformational restriction I nflammatory bowel disease (IBD) represents a group of chronic inflammatory lesions of unknown etiology that affect the digestive tract. 1 The CB 2 cannabinoid receptor emerged as a promising therapeutic target in the treatment of these pathologies. Indeed, this GPCR has been identified within the gastrointestinal tract and plays a key role in the regulation of intestinal inflammation.
2 Additionally, the CB 2 receptor agonists have been shown to exert an anti-inflammatory effect both in intestinal epithelial cells and in experimental models of colitis in mice.
In vitro experiments highlighted that CB 2 receptor activation results in suppression of the release of pro-inflammatory cytokines. 3 Data from in vivo studies emphasized the importance of this receptor in mediating protection against experimental colitis. Indeed, the CB 2 receptor selective agonist JWH133 proved to be efficient in reducing colonic inflammation in models of colitis induced by oil of mustard, dextran sulfate sodium (DSS), or 2,4,6-trinitrobenzenesulfonic acid (TNBS) and in the interleukin 10-deficient mouse model of colitis.
4−6 Similarly, the CB 2 receptor selective agonist AM1241 was shown to significantly reduce inflammation in the TNBSinduced colitis model. 5 The involvement of the CB 2 receptor was demonstrated by counteracting the effect with the CB 2 antagonist/inverse agonist AM630 or by evaluating the compounds in CB 2 receptor deficient mice. Moreover, AM630 was shown to exacerbate colitis in wild-type mice. 5 Consistent with these data, we described a series of 4-oxo-1,4-dihydropyridines (CB 2 selective agonists) in which the lead compound, ALICB573 (48 in ref 7) , was shown to protect mice against experimental colitis when administered at 10 mg/kg (i.p. injection). 7 More recently, two isoxazole-based CB 2 agonists were found to be active in the DSS-induced colitis model in mice. 8 Taken together, these different studies provide the proof of concept that CB 2 agonists are effective in reducing colitis and can therefore be considered as promising agents for the treatment of IBD.
In light of these findings, we aimed to develop new CB 2 receptor agonists effective in the treatment of IBD. In terms of ligand profile, the new ligands should (i) display nanomolar affinity for the CB 2 receptor, (ii) behave as agonists, (iii) be selective for the CB 2 receptor over the CB 1 receptor, to limit CNS side effects, and (iv) be active in an experimental model of colitis in rodents.
Our groups previously described a series of 4-oxo-1,4-dihydroquinoline-3-carboxamides as selective ligands of the CB 2 receptor. 9, 10 One of the commonly used strategies in drug design to increase affinity and selectivity of a given "flexible" lead for its pharmacological target is to conformationally constrain it to mimic the so-called bioactive conformation. Therefore, we designed constrained analogues of the 4-oxo-1,4-dihydroquinoline-3-carboxamide series based on a 2H-pyrazolo[4,3-c]quinolin-3(5H)-one scaffold (Figure 1 ).
Our strategy relies on the fact that the amide at the C-3 position of the 4-oxo-1,4-dihydroquinoline ring may adopt different conformations, of which one is the result of a hydrogen bond between the amide (C-3) and the heterocyclic carbonyl (Figure 1) . 11 We hypothesized that this hydrogenbonded conformation may also be the biologically active conformation of this series of ligands. Accordingly, to accurately orientate the aliphatic or aromatic moiety borne by the amide, we built an additional ring that acts as a permanent conformational lock in place of the intramolecular hydrogen bond. A similar strategy was successfully applied to generate potent topoisomerase II inhibitors. 12, 13 Thus, we designed, synthesized, and evaluated against both CB 1 and CB 2 receptors a series of 2H-pyrazolo[4,3-c]quinolin-3(5H)-one based on the already established pharmacophore in the series of 4-oxo-1,4-dihydroquinoline-3-carboxamide. 9, 10 Therefore, the n-pentyl chain was retained at the N-5 position of the rigid heterocycle and we only varied the moieties at the N-2 position and to a lesser extent the C-4 position.
Key 2H-pyrazolo[4,3-c]quinolin-3(5H)-one compounds 8− 27 were prepared by a linear step-by-step synthesis that include the construction of the 4-oxo-1,4-dihydroquinoline scaffold (Scheme 1).
14 The latter was obtained using two different synthetic routes depending on the nature of the R1 substituent (at C-4). The first one consisted of a condensation of aniline and diethyl ethoxymethylenemalonate followed by cyclization into 4-oxo-1,4-dihydroquinoline 2.
9 Subsequent N-alkylation with 1-bromopentane yielded compound 4. The alternative route, allowing the introduction of a phenyl moiety at C-4, starts with the N-alkylation of isatoic anhydride. The resulting product was then reacted with ethyl benzoylacetate in the presence of sodium hydride to afford the desired 4-oxo-1,4-dihydroquinoline 5.
15 The latter as well as its analogue 4 were converted into the more reactive thioxo-derivatives 6 and 7. Finally, the 2H-pyrazolo[4,3-c]quinolin-3(5H)-ones (10−27) were obtained either by reacting 6 and 7 with the corresponding substituted hydrazine or via initial cyclization with monohydrate hydrazine (leading to 8 and 9) and subsequent N-2 alkylation. 14 The affinities of target compounds 8−27 (Table 1) for the human cannabinoid receptors (hCB 1 and hCB 2 ) were determined by a competitive radioligand displacement assay using [ 3 H]-CP-55,940 as the radioligand for both the hCB 2 and hCB 1 receptors. 7 We also investigated the functional activity on the CB 2 receptor of four representative compounds of this series using a [
35 S]-GTPγS binding assay (Table 2) . 16 The first step of this study was to evaluate the impact of the phenyl substituent at the C-4 position. While in the 4-oxo-1,4-dihydroquinoline series this modification induced a switch in functional activity (from agonist to inverse agonist), 10 in the present case, the substitution was found to be deleterious for the affinity, since none of the C-4 substituted analogues (9−12 and 17−18) displayed activity against CB 2 receptor. As a consequence, no functional activity was measured. Conversely, the absence of a substituent at C-4 provides compounds with very high affinity toward the CB 2 receptor. Therefore, for the rest of our investigations, we decided to leave this position unsubstituted and vary only the moieties at the N-2 position, which were selected on the basis of the previously established pharmacophore (aromatic or aliphatic groups).
The importance of a substituent at the N-2 position was illustrated by the poor affinity of compound 8 (R 2 = H) for both receptor subtypes. Similarly, aromatic groups are generally not well tolerated at this position. Indeed, with the notable exception of 15 (hCB 2 : K i = 29.2 nM), none of the compounds presenting an aromatic group at this position (spaced by an alkyl linker or not) displayed significant affinity for the CB 2 receptor.
In contrast, the introduction of aliphatic substituents at N-2 is crucial for the affinity, since all evaluated compounds presenting an alkyl or cycloalkyl group at this position were found to bind the CB 2 receptor with affinities in the nanomolar range (16 and 21−27). When comparing 16, 24, and 25, it is evident that the distance of the cycloalkyl group from the heterocycle is important, with the methyl linker being optimal. This observation was confirmed when the cycloalkyl was an adamantyl, with 26 (methyl linker) displaying a 67-fold higher affinity than 27 (ethyl linker). In addition, the size of the cycloalkyl group also impacts on the affinity. For instance, when comparing 23, 24, and 26, the compound affinity improves as the cycloalkyl size increases (adamantyl > cyclohexyl > cyclopropyl), with 26 displaying a K i for hCB 2 of 0.39 nM. The drastic loss of affinity when the cycloalkyl is replaced by a phenyl group is noteworthy (24 or 26 vs 19). Lastly, linear alkyl chains are also well tolerated, as evidenced by the high affinity of compounds 21 and 22.
Interestingly, none of the evaluated compounds displayed affinity for the hCB 1 receptor (hCB 1 : K i > 3000 nM), pointing at this series as highly selective for the hCB 2 receptor.
From a functional activity perspective, compounds 16 and 24−26 showed a profile of CB 2 partial agonist with EC 50 values ranging from 5.4 nM to 204 nM and E max values on the order of 150% (Table 2 ). In this assay CB 2 receptor full agonist (R)-(+) WIN 55,212-2 displayed an EC 50 value of 24.5 nM and an E max value of 207%, while SR144528 (inverse agonist) had an EC 50 of 1.8 nM and an E max value of 21.6%. The rigidification approach has no effect on the functional activity as the parent 4-oxo-1,4-dihydroquinoline derivatives were also described as agonists. 7 It is instructive to compare the CB 2 affinity of our lead compound 26 with its analogue in the 4-oxo-1,4-dihydroquino- Our results suggest that the rigidification strategy allows an increase in affinity for the CB 2 receptor while not impacting the functional activity. In addition, very high selectivity for the CB 2 receptor over the CB 1 receptor was achieved. This contrasts with a previously reported study on this series that suggested that the 2H-pyrazolo[4,3-c]quinolin-3(5H)-one was not a good template for designing CB 2 selective ligands, since all of the described ligands behaved as low micromolar/high nanomolar dual CB 1 /CB 2 ligands. 17 We demonstrate herein that high affinity for the CB 2 receptor and selectivity over the CB 1 receptor could be achieved using this template, when both the N-2 and N-5 positions are substituted with an alkyl or cycloalkyl group.
To investigate potential binding modes, compound 26 and its 4-quinolone analogue (ALICB353) was docked into an agonist-biased state model of the CB 2 receptor. 18 In contrast with ALICB353, which produced diverse docking solutions, 26 is not only well tolerated but selects exclusively docking poses that fit in a unique binding mode, satisfying interactions with critical amino acids known to bind reference CB 2 agonists ( Figure S1 in the Supporting Information). The most representative docking pose for each molecule shows both the adamantyl group in a hydrophobic cavity formed by helices 2 (Phe87, Phe91, Phe94) and 3 (Phe106, Ile110, Val 113), as well as a common hydrogen bond with the hydroxyl group of Ser285 (Figure 2) . The docking poses of the central heterocycle and n-pentyl, however, differ slightly for the two compounds. The tricyclic ring of 26 orients orthogonally to the 4-quinolone scaffold of ALICB353, and the n-pentyl chain of 26 extends toward a hydrophobic cavity formed by helices 5 (Phe200, Leu201) and 6 (Val261, Met265) whereas it folds behind the 4-quinolone ring, toward extracellular loop 2 (Leu182, Leu192) in the case of ALICB353.
Our lead compound in this series (26) 19 was evaluated in a mouse model of acute colitis induced by TNBS using a previously described protocol. 20 Compound 26 was orally administered (in carboxymethyl cellulose, CMC) once daily at dosages of 0.1, 1, and 10 mg/kg over 7 days, starting 2 days before colitis induction. Control mice were treated with vehicle only (CMC).
We examined survival rates during the full length of the study and evaluated the body weight loss before euthanasia of the animals (5 days after TNBS administration). We noted that mice treated with 26 show reduced mortality compared to their untreated counterparts ( Figure 3A) . Moreover, daily treatment with compound 26 attenuated, in a dose-dependent manner, body weight loss generally observed during the development of TNBS colitis ( Figure 3B ).
After euthanasia of the different groups, the colon of each mouse was examined and damages were assessed using a semiquantitative scoring system. Mice that received the vehicle only showed macroscopic colitis reflected by thickening of the bowel and areas of ulceration (macroscopic score of 4.9, Figure  4A ). Compound 26 exerts a dose-dependent decrease in macroscopic score ( Figure 4A) , with a very strong effect when administered orally at 10 mg/kg (1.7 vs 4.9). This protective effect was confirmed by the results of the histological evaluation. Indeed, 26 was able to attenuate the histological score by 65% ( Figure 4B ). We also quantified colon levels of TNFα and Il-1β, two cytokines involved in the inflammatory response leading to epithelial injury. As can be seen from Figure  4C and D, compound 26 completely abolished Il-1β mRNA expression but failed to significantly decrease TNFα mRNA expression.
All together, the above data clearly support that compound 26 protects mice against experimental colitis after oral administration in a dose-dependent manner, an effect attributed in part to the strong anti-inflammatory property of this compound. Although different studies have already emphasized the efficacy of CB 2 agonists in colitis, 4−8 all were active after i.p. injection, which from a drug development perspective is not desirable. Favorably, compound 26 is active in a mouse model of colitis after oral administration.
Compound 26 has also been profiled for in vitro metabolic stability, plasma protein binding, intestinal absorption, and hERG toxicity (Table 3) . 21 It was found that 26 binds strongly to plasma proteins, resulting in less than 1% being in the free form. In the in vitro CACO-2 assay, 26 showed very poor permeability (P app = 0.8 × 10 −6 cm·s −1 ). The CACO-2 assay, however, might not be reflective of the intestinal permeability in the case of colitis, where there will be substantial intestinal lesions. It is noteworthy that little inhibition of P-gp was observed in the calcein-AM functional assay (30.6% inhibition at 10 μM). Unfortunately compound 26 does show some hERG affinity (35.5% inhibition of tail current at 1 μM) and so may have some toxicity at a high dose. Compound 26 did however show good in vitro metabolic stability, with 64% of compound remaining after 60 min of incubation with human liver microsomes. The DMPK-tox profile of compound 26 needs to be improved, and future optimization regarding this series will have to focus on this particular point.
In summary, the present study shows that 2H-pyrazolo[4,3-c]quinolin-3(5H)-ones, constrained analogues of 4-oxo-1,4-dihydroquinolines, are potent and highly selective CB 2 receptor agonists. The rigidification approach applied in this paper resulted in increased affinity for the CB 2 receptor while not altering the functional activity. Despite displaying a nonideal in vitro DMPK-Tox profile, compound 26 (ALICB459), the lead of this series, exerts a strong protective effect in the experimental model of TNBS-induced colitis. This effect was achieved after oral administration and was shown to be dosedependent.
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